Clinical trials: Lipodystrophy
HIV Infections, HIV-Associated Lipodystrophy Syndrome
Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
The aim of this randomized study is to compare the occurrence of lipoatrophy in HIV-1 infected, naive patients receiving either a nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy with…
- Trial name
- NCT00122668
- Testing
- non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitor
- Where
- France
- Volunteers
- 112 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Eye Manifestations
Ocular Surface Changes in Patients With Cystic Fibrosis
Cystic fibrosis(CF) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.It is caused by mutations in the protein-coding gene which function as the cystic fibrosis…
- Trial name
- NCT00345280
- Testing
- impression cytology, obtain the tear fluid
- Where
- Poland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Bialystok
Lipodystrophy, Dunnigan Syndrome
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
The objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation.
- Trial name
- IRAP-DUN 2 (NCT05424913)
- Testing
- research-specific blood sample
- Where
- Reunion
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
HIV Infections, Cardiovascular Disease
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood.
- Conditions
- HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy
- Trial name
- WU197 (NCT00656851)
- Testing
- Pioglitazone, Exercise Training
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV-Associated Lipodystrophy Syndrome
Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
Aim: To assess the safety on the progression of HIV infection and the efficacy on the evolution of metabolic parameters and body fat of either viral load- or CD4 cell-driven strategies of intermittent treatment in chronically…
- Trial name
- NCT00646984
- Testing
- Standard continuous antiretroviral therapy, CD-4 guided therapy interruption, Viral load driven treatment interruption
- Where
- Spain
- Volunteers
- 147 people
- Sponsor
- Hospital Clinic of Barcelona
Diabetes, Lipodystrophy
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
Background: Partial lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes.
- Conditions
- Diabetes, Lipodystrophy, Hyperlipidemia
- Trial name
- NCT02262806
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Facial Lipoatrophy, Morphological Asymmetry of the Face
Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars
In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® FILLER, and then will return for follow-up assessments…
- Conditions
- Facial Lipoatrophy, Morphological Asymmetry of the Face, Debilitating Scars
- Trial name
- FLASH 1 (NCT03050723)
- Testing
- Princess® FILLER
- Where
- 3 sites in Austria
- Volunteers
- 53 people
- Sponsor
- Croma-Pharma GmbH
Prostate Cancer, Renal Cancer
64Cu-GRIP B in Patients With Advanced Malignancies
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET)…
- Conditions
- Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor
- Trial name
- NCT05888532
- Testing
- Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Rahul Aggarwal
Insulin Receptor Mutation, Partial Lipodystrophy
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
Background: Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant.
- Trial name
- NCT05470504
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections, Lipodystrophy
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
The purpose of this study is to learn whether changing from a type of anti-HIV drug called a protease inhibitor (PI) to another type of anti-HIV drug will help to lower the amount of fats or sugars in the blood.
- Trial name
- NCT00021463
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz
- Where
- 11 sites in United States
- Volunteers
- 342 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Pulmonary Hypertension Biorepository and Registry
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary
- Trial name
- PHBR (NCT04808596)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Kansas Medical Center
Generalised Lipodystrophy, Partial Lipodystrophy
MEASuRE: Metreleptin Effectiveness And Safety Registry
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
- Trial name
- MEASuRE (NCT02325674)
- Testing
- Metreleptin
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
HIV-Associated Lipodystrophy, HIV Infections
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial lipoatrophy, randomised in a 1:1 ratio to…
- Trial name
- NCT00126308
- Testing
- poly-L-lactic acid
- Where
- 18 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
Cicatrix, Lipodystrophy
Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects
The Research Question of the present study is the following: in a population of men and women presenting dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects) will Plenhyage® significantly…
- Conditions
- Cicatrix, Lipodystrophy, Plaque
- Trial name
- NCT05239117
- Testing
- Plenhyage
- Where
- Romania
- Volunteers
- 48 people
- Sponsor
- I.R.A. Istituto Ricerche Applicate S.p.A.
HIV Infection
A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine
The purpose of this study is to compare the body fat distribution in Human Immunodeficiency Virus-1 (HIV-1) infected patients receiving, since the beginning and for at least two years, an antiretroviral therapy based on efavirenz…
- Trial name
- LYNX (NCT01159743)
- Where
- 26 sites in Spain
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Lipodystrophy
Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy
The aim of this study is to determine the safety of the autologous transplantation of adipose-derived stem cells in the treatment of lipodystrophies.
- Trial name
- AADSCTPL (NCT00715546)
- Testing
- autologous transplantation of liposuction material enriched with adipose-derived stem cells
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Irmandade Santa Casa de Misericórdia de Porto Alegre
HIV Infections, Type 2 Diabetes
Exercise and Pioglitazone for HIV-Metabolic Syndromes
The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d) with and without aerobic and strength exercise training for reducing glucose intolerance and central adiposity in HIV-infected people.
- Conditions
- HIV Infections, Type 2 Diabetes, Obesity, HIV
- Trial name
- NCT00639457
- Testing
- Pioglitazone, Exercise training
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diffuse Large B-Cell Lymphoma
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
- Trial name
- NCT06755775
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Ruijin Hospital
Type 1 Diabetes Mellitus
The Skin Barrier in Users of Diabetes Devices
Diabetes technology (insulin pumps and continuous glucose monitoring) have become standard of care in children with type 1 diabetes.
- Trial name
- StenoLin (NCT06856954)
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Jannet Svensson
Partial Lipodystrophy
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
- Trial name
- NCT06484868
- Testing
- Metreleptin
- Where
- 12 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Amryt Pharma